APA (7th ed.) Citation

Schmitt, C., Grundt, A., Buchholtz, C., Scheuer, L., Benner, A., Hensel, M., . . . Leo, E. (2006). One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near? Leukemia research, 30(12), . https://doi.org/10.1016/j.leukres.2006.01.014

Chicago Style (17th ed.) Citation

Schmitt, Christina, Alexander Grundt, Christian Buchholtz, Lars Scheuer, Axel Benner, Manfred Hensel, Anthony Dick Ho, and Eugen Leo. "One Single Dose of Rituximab Added to a Standard Regimen of CHOP in Primary Treatment of Follicular Lymphoma Appears to Result in a High Clearance Rate from Circulating Bcl-2/IgH Positive Cells: Is the End of Molecular Monitoring Near?" Leukemia Research 30, no. 12 (2006). https://doi.org/10.1016/j.leukres.2006.01.014.

MLA (9th ed.) Citation

Schmitt, Christina, et al. "One Single Dose of Rituximab Added to a Standard Regimen of CHOP in Primary Treatment of Follicular Lymphoma Appears to Result in a High Clearance Rate from Circulating Bcl-2/IgH Positive Cells: Is the End of Molecular Monitoring Near?" Leukemia Research, vol. 30, no. 12, 2006, https://doi.org/10.1016/j.leukres.2006.01.014.